Company intelligence / Profile preview

Ciprés Grupo Médico

Mexico
Ownership
Private
Development stage
Other
01

Overview

Ciprés Grupo Médico has published peer-reviewed research involving mutation screening for the FOXE1 gene in patients with complex syndromes including cleft lip, hypothyroidism, and thyroid carcinoma. The group appears to specialize in genomic DNA isolation and molecular diagnostics for rare or complex diseases.

Therapeutic areas
OtherOncologyEndocrinologyRare Diseases
Modalities
Genetic testingGenomic analysis
Industry
Molecular Diagnostics

Beyond the preview

Go deeper on Ciprés Grupo Médico.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ciprés Grupo Médico.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call